Pipeline

Proof of Principle: Dyrnamix patented biomarker distinguishes patients most likely to benefit from cardiac resynchronization therapy for Congestive Heart Failure

Dyrnamix has identified an

exRNA based non-invasive biomarker for predicting patient response to cardiac resynchronization therapy (CRT) that is more accurate than currently established methods.

What:

Cardiac Resynchronization Therapy (CRT)

  • Established treatment for patients with Congestive Heart Failure

  • Improves morbidity and mortality 

  • $30,000 per procedure

  • $8.8 bn global market

Why: 30% of patients

don't respond

  • Response linked to positive cardiac remodeling

  • Estimated cost in the EU alone of >$7 bn due to patients that don’t respond to therapy

What’s Next: Dyrnamix extracellular RNA

  • Predicts positive cardiac remodeling

  • Predicts positive response to cardiac resynchronization therapy and improvement in symptoms

  • Ability to distinguish which patients most likely to benefit from cardiac resynchronization therapy better than established methods

©2017 by Dyrnamix Inc.